Journal article
Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease
Journal of Alzheimer's disease, v 28(2)
2012
PMID: 21987594
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Therapeutic options for Alzheimer's disease are currently limited to symptomatic treatment that only provides modest and temporary maintenance of cognitive and memory functions, without altering disease progression. Although a variety of therapeutics targeting amyloid production or plaque degradation as well as tau hyperphosphorylation and aggregation have been proposed, examined in pre-clinical models and introduced into clinical trials, many have failed to provide significant therapeutic benefit. Concerns over the adequacy of currently used pre-clinical models, in addition to questions pertaining to the timing of therapeutic administration, vis-à-vis synaptic and neuronal loss have been raised, and are further complicated by the genetic diversity of individual patients. This review will provide a brief overview of Alzheimer's disease pathophysiology and the currently approved therapeutics, while the main section will focus on therapeutics currently evaluated in pre-clinical models and clinical trials.
Metrics
Details
- Title
- Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease
- Creators
- Christopher Haas - Drexel University
- Publication Details
- Journal of Alzheimer's disease, v 28(2)
- Publisher
- IOS Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Civil, Architectural, and Environmental Engineering
- Web of Science ID
- WOS:000300008800001
- Scopus ID
- 2-s2.0-84856990182
- Other Identifier
- 991019173795504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Neurosciences